Author’s reply to TimimiBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6621 (Published 06 November 2013) Cite this as: BMJ 2013;347:f6621
- Iain McClure, consultant child and adolescent psychiatrist1
- 1Royal Hospital for Sick Children, Edinburgh EH9 1LF, UK
Given the increasing costs of stimulant use,1 and the convincing argument about insufficient evidence that benefits outweigh harms in long term use for attention-deficit/hyperactivity disorder (ADHD) “of any severity,”2 3 isn’t it time that the Department of Health investigated the cost-benefit profile for such drug use? To decide on the best approach for our children, we need to balance the playing field. Government should match the considerable financial investment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial